Prospective Evaluation of Stereotactic Body Radiotherapy for Metastatic Prostate Cancer

NCT02206724 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2018-04-20

No results posted yet for this study

Summary

The investigators aim to test the safety and feasibility of prostate gland stereotactic body radiotherapy (SBRT) plus best systemic therapy in newly diagnosed metastatic prostate cancer.

Conditions

Interventions

RADIATION

STEREOTACTIC BODY RADIOTHERAPY to the prostate gland

Sponsors & Collaborators

  • Sharp HealthCare

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-16
Primary Completion
2018-04-17
Completion
2018-04-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02206724 on ClinicalTrials.gov